alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Transport Transports 

Canada Canada

 TP 7245E

 

AIRWORTHINESS DIRECTIVE

The following airworthiness directive (AD) may be applicable to an aircraft which our records indicate is registered in your name. ADs are issued pursuant to Canadian 

Aviation Regulation (CAR) 521 Division X. Pursuant to CAR 605.84 and the further details of CAR Standard 625, Appendix H, the continuing airworthiness of a Canadian registered aircraft is contingent upon compliance with all applicable ADs. Failure to comply with the requirements of an AD may invalidate the flight authorization of the aircraft. Alternative means of compliance shall be applied for in accordance with CAR 605.84 and the above-referenced Standard. 

This AD has been issued by the Continuing Airworthiness Division (AARDG), National Aircraft Certification Branch, Transport Canada, Ottawa, telephone 613 952-4357

Pursuant to CAR 202.51 the registered owner of a Canadian aircraft shall, within seven days, notify the Minister in writing of any change of his or her name or address. 

To request a change of address, contact the Civil Aviation Communications Centre (AARC) at Place de Ville, Ottawa, Ontario K1A 0N8, or 1-800-305-2059, or www.tc.gc.ca/civilaviation/communications/centre/ address.asp 

24-0022 (01-2005)

1/1 No.

CF-2010-32

Issue Date 

30 September 2010 

Number: CF-2010-32 

Subject: Over-torque of Tailboom Attachment Hardware 

Effective: 13 October 2010 

Applicability: Bell Helicopter Textron Canada Ltd. Model 427 helicopter serial number 56001 

through 56084, 58001 and 58002. 

Compliance: Within 150 hours air time or 90 days, whichever comes first after the effective date 

of this directive, unless already accomplished. 

Background: A review of the tailboom attachment installation has determined that the torque value of 

the tailboom attachment bolts specified in the maintenance manual and applied during 

manufacturing, exceeded the torque range recommended for the bolts. 

This situation, if not corrected, can lead to bolt failure, detachment of the tailboom and 

loss of control of the helicopter. To correct the problem, the tailboom attachment 

hardware has to be replaced. 

Corrective 

Actions: 

Replace the tailboom attachment hardware and perform a torque check of the tailboom 

attaching bolts/nuts at all four attachment positions at intervals of no less than 1 but not 

exceeding 5 hours air time following hardware replacement until torque stabilizes at all 

positions. Carry out the above corrective actions in accordance with instructions outlined 

in Bell Helicopter Alert Service Bulletin 427-10-31, dated 1 March 2010 or later revisions 

approved by the Chief, Continuing Airworthiness, Transport Canada. 

Authorization: For Minister of Transport, Infrastructure and Communities 

ORIGINAL SIGNED BY 

Derek Ferguson 

Chief, Continuing Airworthiness 

Contact: Bogdan Gajewski, Continuing Airworthiness, Ottawa, telephone 613-952-4357, facsimile 

613-996-9178 or e-mail CAWWEBFeedback@tc.gc.ca or any Transport Canada Centre.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   6-MOS
<FISCAL-YEAR-END>                          JAN-30-1999             JAN-30-1999
<PERIOD-START>                             MAY-03-1998             FEB-01-1998
<PERIOD-END>                               AUG-01-1998             AUG-01-1998
<CASH>                                           5,137                   5,137
<SECURITIES>                                         0                       0 
<RECEIVABLES>                                    5,290                   5,290 
<ALLOWANCES>                                         0                       0 
<INVENTORY>                                     40,992                  40,992 
<CURRENT-ASSETS>                                53,227                  53,227 
<PP&E>                                         171,911                 171,911 
<DEPRECIATION>                                  69,854                  69,854 
<TOTAL-ASSETS>                                 162,319                 162,319 
<CURRENT-LIABILITIES>                           39,327                  39,327 
<BONDS>                                         25,466                  25,466 
<PREFERRED-MANDATORY>                                0                       0 
<PREFERRED>                                          0                       0 
<COMMON>                                        78,741                  78,741 
<OTHER-SE>                                           0                       0 
<TOTAL-LIABILITY-AND-EQUITY>                   162,319                 162,319
<SALES>                                        100,149                 193,839
<TOTAL-REVENUES>                               100,149                 193,839
<CGS>                                           76,445                 146,722
<TOTAL-COSTS>                                   76,445                 146,722
<OTHER-EXPENSES>                                     0                       0
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                 935                   1,847
<INCOME-PRETAX>                                    403                     697
<INCOME-TAX>                                       217                     455
<INCOME-CONTINUING>                                186                     242
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                       186                     242
<EPS-PRIMARY>                                     0.02                    0.03
<EPS-DILUTED>                                     0.02                    0.03
        

</TABLE>
<PAGE>

EXHIBIT 11

                          DURA PHARMACEUTICALS, INC.
              STATEMENTS RE COMPUTATIONS OF NET INCOME PER SHARE



                                                    THREE MONTHS ENDED
                                                         MARCH 31,
                                                ---------------------------
                                                    1996           1997
                                                ------------   ------------
PRIMARY NET INCOME PER SHARE:                           (unaudited)

Net Income . . . . . . . . . . . . . . . . . .  $  4,056,669   $  8,786,698
                                                ------------   ------------
                                                ------------   ------------

Weighted Average Number of Common and Common
 Equivalent Shares:
  Common stock . . . . . . . . . . . . . . . .    31,376,316     43,351,112
  Stock options. . . . . . . . . . . . . . . .     1,932,038      1,174,639
  Warrants . . . . . . . . . . . . . . . . . .     2,391,264      2,714,066
                                                ------------   ------------
    Total  . . . . . . . . . . . . . . . . . .    35,699,618     47,239,817
                                                ------------   ------------
                                                ------------   ------------

Net Income per Share . . . . . . . . . . . . .  $       0.11   $       0.19
                                                ------------   ------------
                                                ------------   ------------

FULLY DILUTED NET INCOME PER SHARE:

Net Income . . . . . . . . . . . . . . . . . .  $  4,056,669   $  8,786,698
                                                ------------   ------------
                                                ------------   ------------

Weighted Average Number of Common and Common 
 Equivalent Shares Assuming Issuance of All
 Dilutive Contingent Shares:
  Common stock . . . . . . . . . . . . . . . .    31,376,316     43,351,112
  Stock options. . . . . . . . . . . . . . . .     2,089,796      1,174,028
  Warrants . . . . . . . . . . . . . . . . . .     2,459,278      2,713,828
                                                ------------   ------------
    Total  . . . . . . . . . . . . . . . . . .    35,925,390     47,238,968
                                                ------------   ------------
                                                ------------   ------------

Net Income per Share . . . . . . . . . . . . .  $       0.11   $       0.19
                                                ------------   ------------
                                                ------------   ------------
#### Bago v Ford Motor Company,

No. 90760.

In lieu of granting leave to appeal, the case is remanded to the Court of Appeals for consideration as on leave granted. MCR 7.302(F)(1). Court of Appeals No. 129876.
C OURT OF A PPEALS FOR THE

F IRST D ISTRICT OF T EXAS AT H OUSTON



### M EMORANDUM 

### O RDER

Cause No 01

- 09

- 00 328

- CV, Samson Lone Star, LP n/k/a Samson Lone Star, LLC v. Hooks et al.

An appeal from the 60th District Court of Jefferson County, Texas, Trial Court Cause

No. B173008

- B

, the Hon. Gary Sanderson , presiding.

On June 15 , 2012

, appellees moved for rehearing of this Court ’s May 31 , 2012 opinion in

this case. It is ordered that the response of the appellants is due Wednesday

, August 1 5

, 201 2

.

It is so ORDERED.

Judge’s sign ature: /s/ Evelyn V. Keyes

Acting individually

Date: July 27, 2012
Amendment No. 1 to Warrant to Purchase Stock Agreement, dated February 19, 2009



 Exhibit 4.14 
 AMENDMENT NO. 1 TO WARRANT 
 TO 
 PURCHASE COMMON STOCK 
 THIS AMENDMENT NO. 1 TO WARRANT TO PURCHASE COMMON STOCK (this “Amendment”) is entered into as of the 19th day of February
2009, by and between ARCA biopharma, Inc., a Delaware corporation (f/k/a Nuvelo, Inc.) and Atlas Venture Fund VII, L.P. 
 Recitals

 A. The Holder was previously issued a Warrant to Purchase Common Stock dated as of October 10, 2008 (the “Warrant”).
Capitalized terms used in this Amendment, but not otherwise defined in this Amendment, shall have the meanings assigned to them in the Warrant. 
 B. The
Holder and ARCA biopharma, Inc., a Delaware corporation (f/k/a Nuvelo, Inc.) desire to amend the Warrant to reflect the closing of the Merger and the exchange of the common stock of the Corporation (as defined below) for the common stock of ARCA
biopharma Colorado, Inc., a Delaware corporation (f/k/a ARCA biopharma, Inc.) in connection with such closing. 
 Amendments 

 1. The definition of the term “Exercise Price” in Section 1(b) of the Warrant shall be deleted in its entirety and replaced with the
following: 
 “(b) “Exercise Price” shall mean $9.7406, subject to adjustment pursuant to the terms of the
Warrant, including Section 5 of the Warrant.” 
 2. The definition of the term “Exercise Shares” in Section 1(c) of the Warrant
shall be deleted in its entirety and replaced with the following: 
 “(c) “Exercise Shares” shall mean 75,449
shares of common stock of the Corporation (the “Common Stock”) issuable upon the exercise of the Warrant, subject to adjustment pursuant to the terms of the Warrant, including Section 5 of the Warrant.” 
 3. The following defined term shall be added to Section 1 of the Warrant: 
 “(e) “Corporation” shall mean ARCA biopharma, Inc. a Delaware corporation (f/k/a Nuvelo, Inc.).” 
 4. Except for revisions expressly set forth in this Amendment, the parties hereby ratify and confirm the terms of the Warrant in their entirety. 







 IN WITNESS WHEREOF, the undersigned have executed this Amendment to be effective as of the date first set
forth above. 
  

									
	Corporation:	 		 	Holder:
			
	ARCA BIOPHARMA, INC.	 		 	Atlas Venture Fund VII, L.P.
			
		 		 	 By: Atlas Venture Associates VII, L.P.
 its
General Partner

			
		 		 	 By: Atlas Venture Associates VII, Inc.
 its
General Partner

					
	By:	 	/s/ Christopher D. Ozeroff	 		 	Signature:	 	/s/ Kristen Laguerre
		 	Christopher D. Ozeroff, Executive Vice	 		 	Name: Kristen Laguerre
		 	of Business Development and General Counsel	 		 	Title: Vice President
Exhibit 23





CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We consent to the incorporation by reference in Registration Statements No. 333-76518, No. 333-70135, No. 333-82673, No. 333-35978, No. 333-40256, No. 333-134009, No. 333-144058, No. 333-151474, No. 333-160468 and No. 333-169074 on Form S-8 and No. 333-152751 on Form S-3 of our reports dated  February 28, 2011, relating to the financial statements of M/I Homes, Inc., and the effectiveness of M/I Homes, Inc.'s internal control over financial reporting, appearing in this Annual Report on Form 10-K of M/I Homes, Inc. for the year ended December 31, 2010.





/s/DELOITTE & TOUCHE LLP


Columbus, Ohio


February 28, 2011
IN THE SUPREME COURT OF THE STATE OF MONTANA

DA 20-0616

_________________

BENJAMIN M. DARROW,

 Petitioner and Appellant,

 v.

THE EXECUTIVE BOARD OF THE MISSOULA 

COUNTY DEMOCRATIC CENTRAL 

COMMITTEE, and DAVID KENDALL, 

individually, and in his position as Chair of

the MISSOULA COUNTY DEMOCRATIC 

CENTRAL COMMITTEE,

 Defendants and Appellees.

O R D E R

_________________

Appellant Benjamin M. Darrow was granted an extension of time to file and serve 

his opening brief on or before April 8, 2021. The opening brief is now overdue.

THEREFORE,

IT IS ORDERED that Appellant shall prepare, file and serve the opening brief on 

appeal no later than June 2, 2021. Failure to file the brief within that time will result in 

dismissal of this appeal with prejudice and without further notice. 

The Clerk is directed to provide a copy of this Order to Appellant Benjamin M. 

Darrow and to all counsel of record. 

Electronically signed by:

Mike McGrath

Chief Justice, Montana Supreme Court

May 5 2021

05/05/2021

Case Number: DA 20-0616
UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF OHIO

EASTERN DIVISION

PREMIER DEALER SERVICES,

INC.,

Plaintiff,

 Case No. 2:18-cv-735

v. JUDGE EDMUND A. SARGUS, JR.

 Magistrate Judge Chelsey M. Vascura

ALLEGIANCE

ADMINISTRATORS, LLC, et al.,

 

Defendants. 

ORDER

This matter is before the Court for consideration of Defendant Allegiance Administrators, 

LLC’s (“Allegiance”) Motion for Stay of Execution Pending Appeal and Approval of Supersedeas 

Bond Amount (“Motion”). (ECF No. 274.) As this Court previously indicated, the Court was 

“inclined to grant Allegiance’s Motion,” but would not do so until Allegiance provided a bond or 

other security to the Court. (ECF No. 281, at PageID # 8244.) Allegiance has since posted a bond 

(ECF No. 287), and Premier Dealer Services, Inc. consents to the stay pending appeal. (ECF No. 

288, at PageID # 8279.) Accordingly, the Court hereby GRANTS Allegiance’s Motion for Stay 

of Execution Pending Appeal. 

IT IS SO ORDERED.

11/21/2023 s/Edmund A. Sargus, Jr.

DATE EDMUND A. SARGUS, JR.

 UNITED STATES DISTRICT JUDGE

Case: 2:18-cv-00735-EAS-CMV Doc #: 292 Filed: 11/21/23 Page: 1 of 1 PAGEID #: 8284
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals Fifth Circuit 

## FILED August 20, 2003 Charles R. Fulbruge III Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 02-21024 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus JAMES KEVIN ESMOND, also known as Tracy L. Eubanks, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Southern District of Texas USDC No. H-00-CR-652-1

-------------------- Before JONES, WIENER, and BENAVIDES, Circuit Judges.
PER CURIAM: * Court-appointed counsel for James Kevin Esmond has moved for leave to withdraw from this appeal and has filed a brief as required by Anders v. California , 386 U.S. 738 (1967). Esmond has received a copy of counsel’s motion and brief but has not filed a response. Our independent review of the brief and the record discloses no nonfrivolous issue. Accordingly, counsel’s motion for leave to withdraw is GRANTED, counsel is excused from further responsibilities herein, and the APPEAL IS DISMISSED.No. 02-21024 -2- See 5 TH C IR . R. 42.2.
UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF OHIO

WESTERN DIVISION

ORLANDO CARTER,

Case No. 1:18-cv-400

Plaintiff, Black, J.

Bowman, M.J.

v. 

COMMISSIONER CHARLES FURMON, et al.,

Defendants.

REPORT AND RECOMMENDATION

On June 7, 2018, Plaintiff Orlando Carter, a prisoner who proceeds pro se and 

who has frequently litigated in this Court, paid the requisite filing fee and filed a new 

complaint against multiple Defendants.

1

 (Doc. 1). On July 11, 2018, the undersigned 

filed a Report and Recommendation (“R&R”) recommending that Plaintiff’s complaint be 

dismissed with prejudice, pursuant to 28 U.S.C. § 1915(e)(2)(B) and 28 U.S.C. § 

1915A(b), for failure to state any federal claim, and further recommending that this Court 

decline to exercise supplemental jurisdiction over any related state-law claims. (Doc. 24). 

That R&R remains pending before the presiding district judge.

Close in time to when the referenced R&R was filed, Defendants filed two separate 

motions to dismiss, and a third group of Defendants filed a motion seeking leave to file 

their answer instantur. The undersigned directed briefing on the three motions to be 

 

1

In addition to previously dismissed cases filed by Plaintiff, a Related Case Memorandum Order docketed 

on December 13, 2018 reflects a relationship between the above-captioned case and other cases currently 

being pursued by Plaintiff. 

Case: 1:18-cv-00400-SJD-SKB Doc #: 38 Filed: 12/18/18 Page: 1 of 3 PAGEID #: 250
2

stayed. (Doc. 25). Upon further consideration, the undersigned finds it more appropriate 

to recommend the denial of the pending motions as rendered moot by the R&R previously 

filed on July 11, 2018. 

Accordingly, IT IS RECOMMMENDED THAT the three motions (Docs. 21, 22, 23) 

be DENIED AS MOOT without prejudice to renew should the presiding district judge reject 

the previously filed R&R. 

 

 s/ Stephanie K. Bowman 

Stephanie K. Bowman 

United States Magistrate Judge

Case: 1:18-cv-00400-SJD-SKB Doc #: 38 Filed: 12/18/18 Page: 2 of 3 PAGEID #: 251
3

UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF OHIO

WESTERN DIVISION

ORLANDO CARTER,

Case No. 1:18-cv-400

Plaintiff, Black, J.

Bowman, M.J.

v. 

COMMISSIONER CHARLES FURMON, et al.,

Defendants.

NOTICE

Pursuant to Fed. R. Civ. P 72(b), any party may serve and file specific, written 

objections to this Report and Recommendation (“R&R”) within FOURTEEN (14) DAYS of 

the filing date of this R&R. That period may be extended further by the Court on timely 

motion by either side for an extension of time. All objections shall specify the portion(s) of 

the R&R objected to, and shall be accompanied by a memorandum of law in support of 

the objections. A party shall respond to an opponent’s objections within FOURTEEN (14) 

DAYS after being served with a copy of those objections. Failure to make objections in 

accordance with this procedure may forfeit rights on appeal. See Thomas v. Arn, 474 U.S. 

140 (1985); United States v. Walters, 638 F.2d 947 (6th Cir. 1981).

Case: 1:18-cv-00400-SJD-SKB Doc #: 38 Filed: 12/18/18 Page: 3 of 3 PAGEID #: 252
Exhibit 99.2

THE  FOLLOWING  CERTIFICATION  ACCOMPANIES  THE ISSUER'S  ANNUAL  REPORT ON FORM
10-KSB/A AND IS NOT FILED, AS PROVIDED IN SEC RELEASE NOS. 33-8212, 34-47551 AND
IC-25967, DATED MARCH 21, 2003.


          Certification Pursuant to 18 U.S.C. Section 1350, As Adopted
                         Pursuant to Section 906 of the
                           Sarbanes-Oxley Act of 2002


In  connection  with  the  Annual  Report  of  BrandPartners  Group,  Inc.  (the
"Company") on Form  10-KSB/A for the year ended  December 31, 2002 as filed with
the Securities and Exchange  Commission on the date hereof (the  "Report"),  the
undersigned, hereby certifies pursuant to 18 U.S.C. ss.1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2)The  information  contained in the Report  fairly  presents,  in all material
respects, the financial condition and results of operations of the Company.



                                             By: /s/  Sharon Burd
                                                 ----------------------------
                                                 Sharon Burd
                                                 Chief Financial Officer

                                                 April 30, 2003


A SIGNED  ORIGINAL OF THIS  WRITTEN  STATEMENT  REQUIRED BY SECTION 906 HAS BEEN
PROVIDED TO THE ISSUER AND WILL BE RETAINED BY THE ISSUER AND  FURNISHED  TO THE
SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.
IV 

117TH CONGRESS 

2D SESSION H. CON. RES. 81 

Expressing the sense of Congress that the United States representative to 

the United Nations Commission on Narcotic Drugs should use the voice, 

vote, and influence of the United States to seek to de-schedule cannabis 

from Schedule I of the Single Convention on Narcotic Drugs of 1961 

and take other related actions. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 21, 2022 

Ms. MACE (for herself and Ms. LEE of California) submitted the following 

concurrent resolution; which was referred to the Committee on Foreign Affairs 

CONCURRENT RESOLUTION 

Expressing the sense of Congress that the United States 

representative to the United Nations Commission on 

Narcotic Drugs should use the voice, vote, and influence 

of the United States to seek to de-schedule cannabis 

from Schedule I of the Single Convention on Narcotic 

Drugs of 1961 and take other related actions. 

1 Resolved by the House of Representatives (the Senate 

2 concurring), That it is the sense of Congress that the 

3 President should direct the United States representative 

4 to the United Nations Commission on Narcotic Drugs to 

5 use the voice, vote, and influence of the United States at 

6 the Commission to seek to de-schedule cannabis from 


pamtmann on DSKBC07HB2PROD with BILLS
2 

•HCON 81 IH 

1 Schedule I of the Single Convention on Narcotic Drugs 

2 of 1961, expunge and forgive penalties relating to can3 nabis for prior offenders, and treat cannabis as a com4 modity similar to other agricultural commodities. 

Æ 


pamtmann on DSKBC07HB2PROD with BILLS